Literature DB >> 1516196

Lipids and lipoproteins in symptomatic coronary heart disease. Distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women. The Bezafibrate Infarction Prevention (BIP) Study Group, Israel.

.   

Abstract

BACKGROUND: Lipid and lipoprotein profiles of coronary heart disease (CHD) patients have usually not included data on high density lipoprotein cholesterol (HDL-C), except in small groups, and have not included information on women. Both aspects are meaningful in the evaluation of patients for risk classification and for the importance of HDL-C in dictating further evaluation. METHODS AND
RESULTS: In the screening phase of a clinical trial, we obtained lipid and lipoprotein levels under Centers for Disease Control-standardized procedures in more than 6,700 men and 1,500 women aged 40-72 years. Mean total cholesterol (TC) was higher in women (by 15-24 mg/dl) but changed little with age. Mean HDL-C, however, progressively increased with increased age for both sexes (34.4 at age of less than 50 years to 37.5 mg/dl at age 65 or older in men and from 41.3 to 44.5 mg/dl for the respective age groups in women). Triglycerides (TG) were lower in elderly groups, particularly in men (151 mg/dl in 65-year-olds versus 189 in counterparts less than 50 years). The number of previous infarctions, severity of congestive heart failure, and severity of angina were negatively correlated with mean HDL-C in a dose-response manner, whereas the association with mean TG was inverted, creating a mirror image of that observed with HDL-C. More than half of patients (52%) with TC less than 200 mg/dl exhibited HDL-C levels consistent with the accepted "high-risk" range of less than 35 mg/dl, whereas an increasing percentage of desirable HDL-C level was found with increasing levels of TC (14% with HDL-C greater than or equal to 45 mg/dl at TC less than 200 mg/dl increasing gradually to 28% in patients with TC greater than 260 mg/dl).
CONCLUSIONS: These results provide previously unavailable information on the lipid profile of female patients and appear to strongly establish the case for obtaining all three standard blood lipid determinations (TC, HDL-C, and TG) in coronary patients as well as in the framework of detecting and classifying individuals at high risk for CHD.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1516196     DOI: 10.1161/01.cir.86.3.839

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  11 in total

1.  Metabolic syndrome is independently associated with increased 20-year mortality in patients with stable coronary artery disease.

Authors:  Arwa Younis; Anan Younis; Boaz Tzur; Yael Peled; Nir Shlomo; Ilan Goldenberg; Enrique Z Fisman; Alexander Tenenbaum; Robert Klempfner
Journal:  Cardiovasc Diabetol       Date:  2016-10-28       Impact factor: 9.951

2.  Primary Low Level of High-Density Lipoprotein Cholesterol and Risks of Coronary Heart Disease, Cardiovascular Disease, and Death: Results From the Multi-Ethnic Study of Atherosclerosis.

Authors:  Haitham M Ahmed; Michael Miller; Khurram Nasir; John W McEvoy; David Herrington; Roger S Blumenthal; Michael J Blaha
Journal:  Am J Epidemiol       Date:  2016-04-18       Impact factor: 4.897

3.  Oxidized high-density lipoprotein is associated with increased plasma glucose in non-diabetic dyslipidemic subjects.

Authors:  Kazuhiko Kotani; Naoki Sakane; Masashi Ueda; Shinichi Mashiba; Yasuyuki Hayase; Kokoro Tsuzaki; Toshiyuki Yamada; Alan T Remaley
Journal:  Clin Chim Acta       Date:  2012-09-06       Impact factor: 3.786

4.  Low ALT Levels Independently Associated with 22-Year All-Cause Mortality Among Coronary Heart Disease Patients.

Authors:  N Peltz-Sinvani; R Klempfner; E Ramaty; B A Sela; I Goldenberg; G Segal
Journal:  J Gen Intern Med       Date:  2015-08-06       Impact factor: 5.128

5.  Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice.

Authors:  Dacheng Peng; Richard A Hiipakka; Qing Dai; Jian Guo; Catherine A Reardon; Godfrey S Getz; Shutsung Liao
Journal:  J Pharmacol Exp Ther       Date:  2008-08-22       Impact factor: 4.030

Review 6.  A reexamination of the PPAR-alpha activation mode of action as a basis for assessing human cancer risks of environmental contaminants.

Authors:  Kathryn Z Guyton; Weihsueh A Chiu; Thomas F Bateson; Jennifer Jinot; Cheryl Siegel Scott; Rebecca C Brown; Jane C Caldwell
Journal:  Environ Health Perspect       Date:  2009-05-15       Impact factor: 9.031

7.  Ethnic Disparity in Mortality Among Ischemic Heart Disease Patients. A-20 Years Outcome Study From Israel.

Authors:  Arsalan Abu-Much; Eyal Nof; Nicola Luigi Bragazzi; Anan Younis; David Hochstein; Arwa Younis; Nir Shlomo; Alexander Fardman; Ilan Goldenberg; Robert Klempfner; Roy Beinart
Journal:  Front Cardiovasc Med       Date:  2021-06-30

8.  Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial.

Authors:  Yaron Arbel; Robert Klempfner; Aharon Erez; Ilan Goldenberg; Sagit Benzekry; Nir Shlomo; Enrique Z Fisman; Alexander Tenenbaum
Journal:  Cardiovasc Diabetol       Date:  2016-01-22       Impact factor: 9.951

9.  Statins Dose-Dependently Exert Significant Chemopreventive Effects Against Various Cancers in Chronic Obstructive Pulmonary Disease Patients: A Population-Based Cohort Study.

Authors:  Chun-Chao Chen; Yi-Ping Hsu; Ju-Chi Liu; Pai-Feng Kao; Li-Chin Sung; Chao-Feng Lin; Wen-Rui Hao; Shing-Hwa Liu; Szu-Yuan Wu
Journal:  J Cancer       Date:  2016-09-13       Impact factor: 4.207

10.  Impaired Fasting Glucose Is the Major Determinant of the 20-Year Mortality Risk Associated With Metabolic Syndrome in Nondiabetic Patients With Stable Coronary Artery Disease.

Authors:  Arwa Younis; Ronen Goldkorn; Ilan Goldenberg; Diklah Geva; Boaz Tzur; Anna Mazu; Anan Younis; Zvi Fisman; Alexander Tannenbaum; Robert Klempfner
Journal:  J Am Heart Assoc       Date:  2017-10-27       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.